| SHORT COMMUNICATION |
|
| Year : 2022 | Volume
: 67
| Issue : 6 | Page : 725-727 |
|
|
Tofacitinib for the treatment of twenty-nail dystrophy: A single case report
Vineet Dube1, Ravi Bhushan2
1 Consultant Dermatologist, Chandrapur, Maharashtra, India
2 Senior Resident, Department of Dermatology, Venereology and Leprology, Government Medical College and Hospital, Chandrapur, Maharashtra, India
Correspondence Address:
Ravi Bhushan
Senior Resident, Department of Dermatology, Venereology and Leprology , Government Medical College and Hospital, Chandrapur, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijd.ijd_492_22
|
|
|
Twenty nail dystrophy refers to the condition of trachyonychia affecting all the twenty nails. The term trachyonychia is used to describe thin brittle nails with excessive longitudinal ridging. Treatment of twenty nail dystrophy is difficult due to poor bioavailability of drugs in nails. Tofacitinib is novel JAK-STAT inhibitor that has been used successfully for the treatment of nail dystrophy with alopecia areata suggests the possibility of the drug being used for twenty nail dystrophy.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
